Eli Lilly and Company (LLY)
NYSE: LLYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:02 PM ET · Delayed 15 min
LLY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.20T
- P/E (TTM)
- 43.72
- Forward P/E
- 26.48
- EPS (TTM)
- $30.81
- Dividend yield
- 0.50% ($6.69)
- Ex-dividend date
- Nov 13, 2026
- 52-week range
- 850.51 – 1,475.25
- Day range
- 1,341.77 – 1,372.05
- Volume / Avg
- 3.54M / 2.60M
- Beta
- —
- Shares outstanding
- 890.75M
52-week range
LLY stock today
Shares of Eli Lilly (LLY) finished lower on Nov 20 at $1,347.11, a drop of 0.30% or $4.01 per share, versus the S&P 500's 3.70% decline. Shares are 8.7% below their 52-week high of $1,475.25, set on Nov 16, 2026 and 58.4% above the 52-week low of $850.51, in the middle of the past year's range. LLY is up 25.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 27.1%.
At 43.7x trailing earnings, Eli Lilly trades above the peer-group median of 38.8x. Its forward P/E of 26.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Eli Lilly pays an annual dividend of $6.69 per share, a 0.50% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Eli Lilly
Company profileEli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. David A. Ricks
- Headquarters
- Indianapolis, IN
- Employees
- 50,000
- Website
- lilly.com
Financial highlights
Full financialsIn fiscal 2025, Eli Lilly generated $65.18 billion in revenue, up 44.7% from fiscal 2024, its 8th consecutive year of revenue growth. Net income was $20.64 billion (+94.9% year over year), for a net margin of 31.7% versus a median of 21.9% in the prior 5 years. Gross margin was 83.0% (up from 81.3%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B |
| Growth | +44.70% | +32.00% | +19.56% | +0.79% | +15.40% |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B |
| EPS (diluted) | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
Analyst forecast
ForecastConsensus (31 analysts)
buy
Avg. price target
$1,468.57+9.02%
- Strong buy 5
- Buy 20
- Hold 4
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $7.22 vs $5.38
- Surprise
- +34.20%
Dividends
Dividend history- Annual dividend
- $6.69
- Dividend yield
- 0.50%
- Last payment
- $1.73
- Ex-dividend date
- Nov 13, 2026
LLY news
All LLY news- SOXX and DRAM Are Down Between 35.6% and 51.9% From Their Highs. Here’s an Even Better Growth Stock ETF to Buy During the Nasdaq Correction.NasdaqMGK, SOXX, DRAM, NVDA
- $1,000 Invested in Eli Lilly 5 Years Ago Is Now Worth Over $5,000. Could It Soar That Much Again by 2031?NasdaqLLY, NVO
- Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?NasdaqNVO, LLY, PFE
- Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain SightNasdaq
- Noteworthy Friday Option Activity: LLY, ROST, CVNANasdaqLLY, ROST, CVNA, UHAL.B
- AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?NasdaqABBV, LLY
- Weekly Buzz: SNY, REGN Score Approvals; MIST Cuts Costs; ABBV, LLY, JNJ Strike DealsNasdaqABBV, BIIB, BMY, ENLV
- Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?NasdaqPFE, LLY, NVO
Eli Lilly peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| JNJJohnson & Johnson | 270.47 | +1.25% | $651.11B | vs LLY |
| ABBVAbbVie Inc. | 286.20 | +0.94% | $505.89B | vs LLY |
| MRKMerck & Company Inc. | 133.72 | +0.69% | $329.65B | vs LLY |
| NVSNovartis AG | 150.47 | -0.50% | $284.18B | vs LLY |
| AZNAstraZeneca PLC | 174.35 | -0.60% | $270.40B | vs LLY |
| ABTAbbott Laboratories | 103.00 | -0.84% | $178.39B | vs LLY |
| NVONovo Nordisk A/S | 37.82 | -2.70% | $166.69B | vs LLY |
| PFEPfizer Inc. | 27.40 | -0.51% | $156.18B | vs LLY |
Indexes, lists and sector
Index membership
Appears in lists
Eli Lilly stock FAQ
What is Eli Lilly's stock price today?
LLY last traded at $1,347.11 as of Nov 20, 4:02 PM EST, down 0.30% on the day. Prices are delayed at least 15 minutes.
Does Eli Lilly pay a dividend?
Yes. Eli Lilly pays $6.69 per share annually, a 0.50% yield. The most recent dividend of $1.73 had an ex-dividend date of Nov 13, 2026.
What is LLY's P/E ratio?
LLY trades at a trailing P/E ratio of 43.72 and a forward P/E of 26.48, compared with a median of 38.8 for its closest peers.
Is Eli Lilly in the S&P 500?
Yes. Eli Lilly (LLY) is a constituent of the S&P 500 index.
Who is Eli Lilly's CEO?
Mr. David A. Ricks is the chief executive officer of Eli Lilly and Company, which has about 50,000 employees.
Has LLY ever split its stock?
Yes. The most recent LLY stock split was a 2-for-1 split on Oct 16, 1997, one of 4 splits on record.
What is the LLY 52-week high?
The 52-week high for LLY is $1,475.25 and the 52-week low is $850.51. The stock is currently 8.7% below its high.